Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

Cribriform pattern with intraductal carcinoma tied to adverse outcomes in Gleason 7 prostate cancer

05 Nov 2019
Prostate cancer is a silent killer. Many may not be aware of the illness until it is too late.

An association exists between cribriform pattern with intraductal carcinoma and adverse outcomes in men with Gleason 7 prostate cancer treated with external beam radiotherapy, reports a study. Cribriform pattern without intraductal carcinoma shows no association.

A total of 237 patients were analysed, with a median follow-up of 117 months (range, 3–236). Based on National Comprehensive Cancer Network risk groups, 24 percent of patients were at favourable intermediate risk, 53 percent unfavourable intermediate risk and 23 percent high risk.

The rates of cribriform pattern without intraductal carcinoma, cribriform pattern with intraductal carcinoma, intraductal carcinoma without cribriform pattern were 36 percent, 13 percent and 0 percent, respectively. Fifty-one percent of patients did not fall in any of these morphologies.

Multivariate analysis indicated the association of cribriform pattern with intraductal carcinoma (hazard ratio [HR], 4.22, 95 percent confidence interval [CI], 2.08–8.53; p<0.0001), prostate-specific antigen 10–20 ng/ml (HR, 1.97, 95 percent CI, 1.03–3.79; p=0.04) and prostate-specific antigen >20 ng/ml (HR, 2.26, 95 percent CI, 1.21–4.23; p=0.01) with worse biochemical recurrence-free survival.

Additionally, only cribriform pattern with intraductal carcinoma correlated with inferior distant metastasis-free survival (HR, 4.18, 95 percent CI, 1.43–12.28; p=0.01) and disease-specific survival (HR, 14.26, 95 percent CI, 2.75–74.04; p=0.0016). Grade group 3, high-risk group and 50-percent positive biopsy cores were associated with cribriform pattern with or without intraductal carcinoma.

Stratification by neither morphology present, cribriform pattern without intraductal carcinoma and cribriform pattern with intraductal carcinoma demonstrated statistically significant differences in biochemical recurrence-free (p=0.00042), distant metastasis-free (p=0.017) and disease-specific survival (p<0.001).

“Future studies may benefit from dichotomizing these two histological entities,” the investigators said.

In this study, men with Gleason 7 (grade groups 2 and 3) prostate cancer treated with dose-escalated external beam radiotherapy with or without androgen deprivation were analysed. Biopsies for the presence of cribriform pattern and/or intraductal carcinoma were also reviewed.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.